(Q35906945)

11 August 2017

1 reference

title

Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer (English)

1 reference

11 August 2017

1 reference

1

Pierre Mongiat-Artus

1 reference

11 August 2017

Pierre Teillac

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

Expert Opinion on Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

5

1 reference

11 August 2017

issue

10

1 reference

11 August 2017

page(s)

2171-2179

1 reference

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2171

Prostate—an extrapituitary source of follicle-stimulating hormone (FSH): Occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2171

Development of GnRH antagonists for prostate cancer: new approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2171

Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2171

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2171

An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2171

Gonadotropin-releasing-hormone-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2171

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.10.2171

10.1517/14656566.5.10.2171

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference